#MetaVia

Fazen Capital

@fazencapital.bsky.social

1 week ago

MetaVia Posts GAAP EPS of -$7.35 MetaVia reported GAAP EPS of -$7.35 on Mar 26, 2026 (Seeking Alpha); institutions must verify cash runway and covenant risk before adjusting exposure.

MetaVia Posts GAAP EPS of -$7.35: MetaVia reported GAAP EPS of -$7.35 on Mar 26, 2026 (Seeking Alpha); institutions must verify cash runway and covenant risk before adjusting exposure. 👈 Read full analysis #MetaVia #GAAP #EarningsReport #CashRunway #FinancialAnalysis

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

MetaVia Obtains IRB Approval to Advance Groundbreaking Obesity Treatment with DA-1726 in Phase 1 Studies MetaVia Inc. has received Important IRB approval for higher-dose Phase 1 studies of DA-1726, a leading dual agonist for weight loss and glucose control.

MetaVia Obtains IRB Approval to Advance Groundbreaking Obesity Treatment with DA-1726 in Phase 1 Studies #United_States #Cambridge #GLP-1 #MetaVia #DA-1726

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

MetaVia Broadens Global Patent Protection for Vanoglipel Until 2035 MetaVia Inc. enhances its patent portfolio for vanoglipel, supporting treatments for metabolic and liver diseases, effective through 2035. Explore their strategic advancements.

MetaVia Broadens Global Patent Protection for Vanoglipel Until 2035 #USA #Cambridge #MetaVia #GPR119 #Vanoglipel

Thiard News@F4F

@newsen.bsky.social

1 month ago

MetaVia Showcases Innovative Therapies for Obesity at Life Sciences Investor Forum Join MetaVia Inc. at the Life Sciences Virtual Investor Forum where they will unveil groundbreaking therapies aimed at tackling obesity and metabolic disorders, featuring a live Q&A session.

MetaVia Showcases Innovative Therapies for Obesity at Life Sciences Investor Forum #USA #Cambridge #MetaVia #DA-1726 #Vanoglipel

Thiard News@F4F

@newsen.bsky.social

1 month ago

MetaVia Secures Global Patent Protection for Innovative Obesity Treatment DA-1726 Until 2041 MetaVia Inc. has secured global patent protection for DA-1726, a promising obesity treatment, covering a unique dual agonist therapy to 2041.

MetaVia Secures Global Patent Protection for Innovative Obesity Treatment DA-1726 Until 2041 #United_States #Cambridge #MetaVia #Obesity_Treatment #DA-1726

Thiard News@F4F

@newsen.bsky.social

2 months ago

MetaVia Unveils Promising AI-Modeling Outcomes Confirming Therapeutic Aims for Vanoglipel MetaVia's latest AI-driven collaboration reveals significant targets for the drug vanoglipel, addressing inflammatory and cardiometabolic diseases. Discover the promising results.

MetaVia Unveils Promising AI-Modeling Outcomes Confirming Therapeutic Aims for Vanoglipel #United_States #Cambridge #MetaVia #Vanoglipel #AI-Modeling

Thiard News@F4F

@newsen.bsky.social

2 months ago

MetaVia Secures $9.3 Million Funding for Innovative Treatments in Cardio-Metabolic Diseases MetaVia Inc. closes a $9.3 million public offering to advance its groundbreaking treatments targeting cardiometabolic diseases and obesity.

MetaVia Secures $9.3 Million Funding for Innovative Treatments in Cardio-Metabolic Diseases #biotechnology #MetaVia #DA-1726

Thiard News@F4F

@newsen.bsky.social

2 months ago

MetaVia Raises $8.1 Million Through Public Stock Offering for Cardiometabolic Innovation MetaVia Inc. announces its $8.1 million public offering aimed at funding the development of treatments for cardiometabolic diseases, including obesity.

MetaVia Raises $8.1 Million Through Public Stock Offering for Cardiometabolic Innovation #USA #Cambridge #MetaVia #DA-1726 #Series_C_Warrants

Thiard News@F4F

@newsen.bsky.social

3 months ago

MetaVia Announces Promising Results from Phase 1b Study of DA-1726 in Obesity Management MetaVia has reported significant advancements in its clinical trial for DA-1726, showcasing remarkable weight loss and positive metabolic effects in obese patients.

MetaVia Announces Promising Results from Phase 1b Study of DA-1726 in Obesity Management #United_States #Cambridge #MetaVia #Obesity_Treatment #DA-1726

Thiard News@F4F

@newsen.bsky.social

3 months ago

MetaVia's Participation and Sponsorship at MASH-TAG 2026 Conference Announced MetaVia Inc. announces its participation and sponsorship at the MASH-TAG 2026 Conference, focusing on cardiometabolic disease innovations in Utah.

MetaVia's Participation and Sponsorship at MASH-TAG 2026 Conference Announced #United_States #Park_City #MetaVia #MASH-TAG #DA-1726

Thiard News@F4F

@newsen.bsky.social

3 months ago

MetaVia Inc. Successfully Meets Nasdaq's Minimum Price Requirements Again MetaVia Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement, essential for maintaining its listing on the exchange.

MetaVia Inc. Successfully Meets Nasdaq's Minimum Price Requirements Again #USA #NASDAQ #Cambridge #MetaVia #cardiometabolic

Thiard News@F4F

@newsen.bsky.social

5 months ago

MetaVia Reports Significant Phase 2a Findings for Vanoglipel in MASH Patients at AASLD 2025 MetaVia Inc. highlights promising Phase 2a data on vanoglipel, showcasing its efficacy in treating patients with presumed MASH during the AASLD Liver Meeting 2025.

MetaVia Reports Significant Phase 2a Findings for Vanoglipel in MASH Patients at AASLD 2025 #United_States #Washington_D.C. #MetaVia #Vanoglipel #Phase_2a_Data

Thiard News@F4F

@newsen.bsky.social

5 months ago

MetaVia Unveils Promising Phase 1 Results of DA-1726 for Obesity at ObesityWeek® 2025 MetaVia Inc. presents groundbreaking Phase 1 and pre-clinical data on DA-1726, showing significant weight loss and potential benefits in cardiometabolic disease treatment.

MetaVia Unveils Promising Phase 1 Results of DA-1726 for Obesity at ObesityWeek® 2025 #United_States #Atlanta #MetaVia #DA-1726 #ObesityWeek

Thiard News@F4F

@newsen.bsky.social

5 months ago

MetaVia to Showcase Groundbreaking Liver Treatment Research at AASLD 2025 MetaVia Inc. will present promising data on Vanoglipel (DA-1241), a novel GPR119 agonist, at the upcoming AASLD Liver Meeting 2025, detailing its hepatoprotective effects.

MetaVia to Showcase Groundbreaking Liver Treatment Research at AASLD 2025 #United_States #Washington,_D.C. #MetaVia #GPR119 #Vanoglipel

Thiard News@F4F

@newsen.bsky.social

5 months ago

MetaVia's DA-1726 Shows Promise at ObesityWeek® 2025 with New Research Presentations MetaVia Inc. announces new findings on DA-1726, a promising therapy for obesity, to be presented at ObesityWeek® 2025, showcasing its efficacy and unique properties.

MetaVia's DA-1726 Shows Promise at ObesityWeek® 2025 with New Research Presentations #USA #Atlanta #MetaVia #DA-1726 #ObesityWeek

Thiard News@F4F

@newsen.bsky.social

7 months ago

MetaVia Inc. Set to Showcase Innovations at Key Conferences Focused on Cardiometabolic Diseases MetaVia Inc. is gearing up for significant industry events where they will present groundbreaking insights on obesity treatments and cardiometabolic health innovations.

MetaVia Inc. Set to Showcase Innovations at Key Conferences Focused on Cardiometabolic Diseases #United_States #Boston #MetaVia #DA-1726 #OXM

Thiard News@F4F

@newsen.bsky.social

8 months ago

MetaVia Inc. Posts Strong Q2 2025 Financial Results Amidst Major Clinical Advancements MetaVia Inc. reports positive financial results for Q2 2025, highlighting advancements in obesity treatment trials and new collaborations in biotechnology.

MetaVia Inc. Posts Strong Q2 2025 Financial Results Amidst Major Clinical Advancements #USA #Cambridge #MetaVia #DA-1241 #DA-1726

Thiard News@F4F

@newsen.bsky.social

8 months ago

MetaVia Expands Phase 1 Trial Duration for DA-1726 to 8 Weeks to Ensure Efficacy MetaVia Inc. has announced an extension of the Phase 1 clinical trial for DA-1726, designed to treat obesity, enhancing both safety and efficacy evaluations over an 8-week period.

MetaVia Expands Phase 1 Trial Duration for DA-1726 to 8 Weeks to Ensure Efficacy #USA #Cambridge #MetaVia #DA-1726 #obesity_research

Thiard News@F4F

@newsen.bsky.social

8 months ago

MetaVia Partners with Syntekabio to Enhance DA-1241 Development with AI Technology MetaVia's collaboration with Syntekabio aims to expand the therapeutic applications of DA-1241, leveraging AI technology for drug discovery and optimization.

MetaVia Partners with Syntekabio to Enhance DA-1241 Development with AI Technology #United_States #Cambridge #MetaVia #DA-1241 #Syntekabio

@drtimos.bsky.social

8 months ago

Obesity Weekly News – July 15th 2025 Obesity Update: Wegovy’s 7.2mg Bid, Rhythm’s Oral Win, TRPV1 Breakthrough & More In this week’s Obesity Updates, we spotlight the […] The post Obesity Weekly News – July 15th 2025 appeared first on LucidQuest Ventures.

FYI: LucidQuest Views >>> Obesity Weekly News – July 15th 2025 #News #ObesityResearch #Bivamelagon #TRPV1 #MetaVia Comment below!

@drtimos.bsky.social

8 months ago

Obesity Weekly News – July 15th 2025 Obesity Update: Wegovy’s 7.2mg Bid, Rhythm’s Oral Win, TRPV1 Breakthrough & More In this week’s Obesity Updates, we spotlight the […] The post Obesity Weekly News – July 15th 2025 appeared first on LucidQuest Ventures.

ICYMI: LucidQuest Views >>> Obesity Weekly News – July 15th 2025 #News #ObesityResearch #Bivamelagon #TRPV1 #MetaVia Comment below!

@drtimos.bsky.social

8 months ago

Obesity Weekly News – July 15th 2025 Obesity Update: Wegovy’s 7.2mg Bid, Rhythm’s Oral Win, TRPV1 Breakthrough & More In this week’s Obesity Updates, we spotlight the […] The post Obesity Weekly News – July 15th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Obesity Weekly News – July 15th 2025 #News #ObesityResearch #Bivamelagon #TRPV1 #MetaVia Comment below!

PRISM MarketView

@prismmarketview.bsky.social

8 months ago

#MetaVia (Nasdaq: #MTVA) has hit a key milestone as it begins dosing in the 48 mg cohort of its Phase 1 obesity trial for DA-1726. Early results showed strong weight loss and metabolic benefits—without titration. Top-line data is expected in Q4.
#MetaVia
prismmarketview.com/metavia-adva...

Thiard News@F4F

@newsen.bsky.social

8 months ago

MetaVia Begins Phase 1 Clinical Trial for Obesity Treatment with DA-1726 Dosing MetaVia Inc. has commenced dosing the first patient in its Phase 1 clinical trial for DA-1726, a novel obesity treatment. This trial aims to establish maximum tolerated doses and gather safety data.

MetaVia Begins Phase 1 Clinical Trial for Obesity Treatment with DA-1726 Dosing #United_States #Cambridge #MetaVia #Obesity_Treatment #DA-1726

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

A digital illustration showing a healthcare professional holding a tablet with a glowing holographic liver surrounded by medical icons, representing liver health innovation by MetaVia Inc.

#MTVA unveils new data showing its liver drug DA-1241 works even better in combo with Efruxifermin—offering new hope for treating MASH. Details coming from #ADA2025.
#MetaVia
prismmarketview.com/metavia-high...

Thiard News@F4F

@newsen.bsky.social

9 months ago

MetaVia's DA-1241 and Efruxifermin Show Promising Results in Combating MASH At the ADA's 85th Scientific Sessions, MetaVia Inc. revealed that its therapy DA-1241 combined with Efruxifermin shows significant liver protection, advancing the fight against MASH.

MetaVia's DA-1241 and Efruxifermin Show Promising Results in Combating MASH #USA #Chicago #MetaVia #DA-1241 #Efruxifermin

PRISM MarketView

@prismmarketview.bsky.social

10 months ago

Multiple hands gently holding blue diabetes awareness ribbons with red blood drop symbols, symbolizing support and care. Image associated with MetaVia Inc.

#MetaVia (Nasdaq: #MTVA) is set to unveil promising preclinical data on its novel GPR119 agonist, DA-1241, at the American Diabetes Association's 85th Scientific Sessions.
prismmarketview.com/metavia-to-p...

Thiard News@F4F

@newsen.bsky.social

10 months ago

MetaVia to Present Innovative DA-1241 Research at ADA's 85th Scientific Sessions MetaVia Inc. will present groundbreaking findings on DA-1241, a GPR119 agonist, at the upcoming ADA's 85th Scientific Sessions in Chicago.

MetaVia to Present Innovative DA-1241 Research at ADA's 85th Scientific Sessions #USA #Chicago #MetaVia #DA-1241 #GPR119

PRISM MarketView

@prismmarketview.bsky.social

10 months ago

$MTVA leads the PRISM Emerging Weight Loss Index, up 18% on Q1 2025 news! Positive Phase 1 results for DA-1726 show powerful weight loss, glucose control, and tolerability—positioning it as a best-in-class obesity treatment.
#MetaVia #PRISMEmergingWeightLossIndex

Thiard News@F4F

@newsen.bsky.social

10 months ago

MetaVia's Promising First Quarter 2025 Results and Breakthroughs in Obesity Treatment MetaVia Inc. announces strong Q1 2025 financial results and showcases promising Phase 1 results for DA-1726, a new obesity treatment, indicating potential best-in-class outcomes.

MetaVia's Promising First Quarter 2025 Results and Breakthroughs in Obesity Treatment #United_States #Cambridge #MetaVia #DA-1241 #DA-1726